Compare Cognizant Technology Solutions Corp (CTSH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs TransMedics Group Inc — how do they compare? Cognizant Technology Solutions Corp trades at $58.02 (market cap $26.40B), while TransMedics Group Inc trades at $87.21 (market cap $3.10B). The key difference: Cognizant Technology Solutions Corp is far larger — about 8.5× TransMedics Group Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CTSH | TMDX | |
|---|---|---|
Market Cap | $26.40B | $3.10B |
Sector | Technology | Technology |
52-Week High | $86.70 | $150.42 |
52-Week Low | $38.73 | $61.99 |
Enterprise Value | $27.44B | $3.49B |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $57.76, down 0.94% on the day, with a bullish technical signal and strong cash flow generation. Recent Q2 2026 earnings missed estimates, but revenue beat, and the company maintains solid profitability with a 10.26% net margin. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience in financial services growth amid AI investments.
The outlook remains cautiously optimistic with upside potential from AI initiatives and large-deal execution, though risks include client spending caution and competitive pressures. Valuation metrics like a P/E of 12.58 suggest room for growth if earnings momentum improves.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
